Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05357885 · ClinicalTrials.gov registry record
Quantitative COVID-19 SARS-CoV-2 Antibody Pre and Post Cardiopulmonary Bypass
A clinical trial, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- 60
- Enrollment target
NCT05357885: Completed study, sponsored by Thomas Jefferson University.
NCT05357885 is a clinical trial that has completed, run by Thomas Jefferson University. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05357885 has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
Study Summary
This study is designed to compare the levels of SARS-CoV-2 antibody prior to cardiopulmonary bypass and after cardiopulmonary bypass (CPB).
Primary Outcome
assess antibody levels before and after CPB.
Interventions
- DIAGNOSTIC_TEST SARS-CoV-2 Antibody test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-11-17 |
| Est. Completion | 2022-03-17 |
What the finished NCT05357885 record still lists
NCT05357885 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which SARS-CoV-2 Antibody test is the first listed.
NCT05357885 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05357885 about?
NCT05357885 is a clinical study titled "Quantitative COVID-19 SARS-CoV-2 Antibody Pre and Post Cardiopulmonary Bypass". This study is designed to compare the levels of SARS-CoV-2 antibody prior to cardiopulmonary bypass and after cardiopulmonary bypass (CPB).
What is the current status of trial NCT05357885?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2021-11-17. Estimated completion is 2022-03-17.
What interventions are being tested in trial NCT05357885?
The interventions under investigation include: SARS-CoV-2 Antibody test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05357885?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI